Skip to main content
. 2018 Jul 4;12:2025–2038. doi: 10.2147/DDDT.S154258

Figure 6.

Figure 6

Figure 6

Subgroup analysis of the relative risk of high-grade adverse events for the combination of ipilimumab and sargramostim versus ipilimumab alone.

Note: (A) Diarrhea; (B) nausea; (C) colitis; (D) fatigue.

Abbreviations: CI, confidence interval; IV, inverse variance; GM-CSF, granulocyte-macrophage colony-stimulating factor; M–H, Mantel–Haenszel.